28 September 2021: Original Paper
Is Continuing Anticoagulation or Antiplatelet Therapy Safe Prior to Kidney Transplantation?
Jose C. Alonso-Escalante ABCDEF* , Lorenzo Machado ABDEF , Kiumars R. Tabar ABDE , Rachell Tindall DE , Ngoc Thai ADE , Tadahiro Uemura ACDEFDOI: 10.12659/AOT.931648
Ann Transplant 2021; 26:e931648
Table 1 Recipient demographics, indication for transplantation, induction, and maintenance immunosuppression.
| WARF (n=23) | ASA/CLOP (n=32) | CTL (n=197) | p Value | |
|---|---|---|---|---|
| Gender (M: F) | 6: 17 | 21: 12 | 118: 79 | 0.01 |
| Mean age (y) | 60 | 62 | 55 | 0.01 |
| Kidney disease (%) | 0.54 | |||
| DM | 39% | 44% | 29% | |
| HTN | 17% | 25% | 17% | |
| Glomerulonephritis | 13% | 13% | 14% | |
| PCKD | 9% | 6% | 12% | |
| Other* | 22% | 12% | 28% | |
| Induction Immunosuppression | 0.01 | |||
| Thymoglobulin | 70% | 72% | 88% | |
| Basiliximab | 30% | 16% | 10% | |
| Other | 0% | 13% | 3% | |
| Maintenance Immunosuppression | ||||
| Tacrolimus | 91% | 91% | 93% | 0.94 |
| Cyclosporine | 3% | 4% | 2% | |
| Other** | 6% | 4% | 5% | |
| * Includes IgA nephritis, lupus nephritis, Alport Syndrome, obstructive uropathy, drug-induced nephritis, cardiorenal syndrome, hepatorenal syndrome; ** includes belatacept, rapamycin, and solumedrol only. | ||||